

May 10, 2017

Company name: Mitsubishi Tanabe Pharma Corporation
Representative: Masayuki Mitsuka
President and Representative Director
Code number: 4508, First Section, Tokyo Stock
Exchange
Contact: Yoshifumi Mifune, General Manager
TEL:+81-6-6205-5211

Differences Between Non-Consolidated Actual Results for FY2015 and FY2016

Mitsubishi Tanabe Pharma Corporation (hereinafter "the Company") informs that differences between non-consolidated actual results for the fiscal year ended March 31, 2016 and the fiscal year ended March 31, 2017 as follows;

1.Differences between non-consolidated actual results between FY2015 and FY2016

(million yen)

	Net sales	Operating profit	Ordinary income	Net income attributable to shareholders of the Company	Net income attributable to shareholders of the Company per share
Actual results(A) (FY2015)	411,483	105,476	108,168	73,233	¥130.54
Actual results(B) (FY2016)	396,319	86,786	89,007	47,908	¥85.40
Differences(B-A)	(15,164)	(18,690)	(19,161)	(25,325)	—
Differences(%)	(3.7)	(17.7)	(17.7)	(34.6)	—

2.Reasons for Differences

With regard to the decrease of net income attributable to shareholders of the Company, lump-sum revenue from licensing out MT-1303 the therapeutic agent for autoimmune disease and TA-8995 the treatment agent for dyslipidemia booked in FY2015, therefore, the operating profit decreased in FY2016. And non-operating income from selling domestic listed stocks incurred in FY2015.

End